Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study
Alimentary Pharmacology & Therapeutics · 2025
DOI: 10.1111/apt.70139 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Saqr Alsakarneh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA. Hauptthemen laut MEDLINE: Arthritis, Psoriatic, Interleukin-17, Inflammatory Bowel Diseases, Psoriasis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
IL‐17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL‐17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL‐17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85–3.39). IL‐17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
- Department of Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
- Department of Medicine, Henry Ford Hospital, Detroit, Michigan, USA.
- Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.
ORCID-Profile: Saqr Alsakarneh, Omar Al Ta'ani
Zitieren
APA
Alsakarneh, S., Al Ta'ani, O., Aburumman, R., Mikhail, I., Hashash, J. G., & Farraye, F. A. (2025). Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70139
Vancouver
Alsakarneh S, Al Ta'ani O, Aburumman R, Mikhail I, Hashash JG, Farraye FA. Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70139
BibTeX
@article{Alsakarneh2025,
author = {Alsakarneh, Saqr and Al Ta'ani, Omar and Aburumman, Razan and Mikhail, Inas and Hashash, Jana G and Farraye, Francis A},
title = {Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL ‐ 17A Inhibitors: A Population‐Based Study},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2025},
doi = {10.1111/apt.70139}
}
EUVIMED